易瑞生物目标价涨幅达44% 37家公司获推荐｜券商评级观察

Core Insights - On November 19, brokerages provided target prices for listed companies, with notable increases for 易瑞生物 (Yirui Biotech), 中国海诚 (China Haicheng), and 健康元 (Health元), showing target price increases of 44.37%, 40.26%, and 26.01% respectively, across the medical device, professional engineering, and chemical pharmaceutical industries [1][2]. Group 1: Target Price Increases - 易瑞生物 (Yirui Biotech) received a target price of 15.00 yuan with a target increase of 44.37% from 华创证券 (Huachuang Securities) [2]. - 中国海诚 (China Haicheng) has a target price of 15.40 yuan, reflecting a 40.26% increase from 国泰海通证券 (Guotai Junan Securities) [2]. - 健康元 (Health元) was assigned a target price of 15.26 yuan, indicating a 26.01% increase from 国泰海通证券 (Guotai Junan Securities) [2]. Group 2: Brokerage Recommendations - A total of 37 listed companies received brokerage recommendations on November 19, with 伊利股份 (Yili Group) receiving recommendations from 3 brokerages, 南方航空 (Southern Airlines) from 1, and 易瑞生物 (Yirui Biotech) from 1 [3]. - 伊利股份 (Yili Group) closed at 29.58 yuan and was recommended by 3 brokerages in the beverage and dairy industry [3]. Group 3: First Coverage - On November 19, 6 companies received initial coverage from brokerages, including 潮宏基 (Chao Hong Ji) with a "Buy" rating from 首创证券 (Shouchuang Securities) [4]. - 海容冷链 (Hairong Cold Chain) received an "Increase" rating from 兴业证券 (Industrial Securities) [4]. - 风华高科 (Fenghua High-Tech) was rated "Buy" by 中邮证券 (China Post Securities) [4].